Art. -Nr.: HY-N0580

Fraxetin

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Fraxetin is isolated from Fraxinus rhynchophylla Hance and has oral bioactivity. Fraxetin has anti-tumor, antibacterial, antioxidant, and anti-inflammatory effects. Fraxetin can induce cell apoptosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.96%
CAS. Nr.: 574-84-5
Formel: C₁₀H₈O₅
Molecular Weight:208.17

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Fraxetin Chemical Structure

CAS. Nr.: 574-84-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
HaCaT	IC₅₀	2.8 μM Compound: Fraxetin	Inhibition of TNFalpha production in UVB irradiated human HaCaT cells administered 2 hrs before irradiation by fluoroimmunoassay Inhibition of TNFalpha production in UVB irradiated human HaCaT cells administered 2 hrs before irradiation by fluoroimmunoassay	[PMID: 17317175]
Neutrophil	IC₅₀	1 μM Compound: fraxetin	Inhibition of TPA-induced ROS production in human neutrophils by chemiluminescence Inhibition of TPA-induced ROS production in human neutrophils by chemiluminescence	[PMID: 15387642]
U-937	CC₅₀	70.2 μM Compound: 2, Fraxetin	Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay	[PMID: 22925447]
U-937	IC₅₀	142.9 μM Compound: 2, Fraxetin	Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting	[PMID: 22925447]

In Vitro

Fraxetin (20-60 μM, 24 h) inhibits the proliferation of MCF-7 cells and induces apoptosis^[1].
Fraxetin (0.02-0.08 mg/ml, 30 min) disrupts the synthesis of nucleic acids and proteins by preventing topoisomerase from binding to DNA, showing significant inhibitory effects on the proliferation of Staphylococcus aureus^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

MCF-7
Concentration:

20, 40, 60 μM
Incubation Time:

24 h
Result:

Inhibited cell proliferation.

Immunofluorescence^[1]

Cell Line:

MCF-7
Concentration:

20, 40, 60 μM
Incubation Time:

24 h
Result:

Condensed chromatin.

RT-PCR^[1]

Cell Line:

MCF-7
Concentration:

20, 40, 60 μM
Incubation Time:

24 h
Result:

Upregulated the expression of Fas and FasL mRNA.

Western Blot Analysis^[1]

Cell Line:

MCF-7
Concentration:

20, 40, 60 μM
Incubation Time:

24 h
Result:

Upregulated Bax and downregulated Bcl-2.

In Vivo

Fraxetin (20-50 mg/kg, gavage, once daily, 24 weeks) has a hepatoprotective effect in mice and also has antioxidant and anti-inflammatory activities^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Ethanol-induced liver fibrosis model in rats ^[3]
Dosage:

20, 50 mg/kg; daily; 24 weeks
Administration:

i.g.
Result:

Reduced serum ALT and AST, weakened tissue pathological changes, upregulated heme oxygenase-1 (HO-1) protein, reduced lipid peroxidation, enhanced liver antioxidant capacity, inhibited CYP2E1 activity, and reduced inflammatory mediators such as TNF-α and IL-1β.

Chemical Information

CAS. Nr. 574-84-5
Appearance Solid
Molecular Weight 208.17
Formel C₁₀H₈O₅
Color Light yellow to yellow
SMILES

O=C1C=CC2=CC(OC)=C(O)C(O)=C2O1
Structure Classification
- Phenylpropanoids
- Coumarins
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All Cell Proliferation/Viability AssayCell Migration/Invasion AssayFlow CytometryIFWB

Sort by:

Journal Impact Factor

Heliyon

Exploration of the mechanism of fraxetin in treating acute myeloid leukemia based on network pharmacology and experimental verification. [Abstract]

2024 Jul 16;10(15):e34717. PMID: 39166080

Fraxetin purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Jul 16;10(15):e34717. [Abstract]

Viability of THP1 and HL60 cells after 24h of Fraxetin (40, 80, 120, 160, 200 μM) treatment.

Fraxetin purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Jul 16;10(15):e34717. [Abstract]

THP1 and HL60 cells were treated with Fraxetin (0, 80, 120, 160 μM) for 24 h, apoptosis rates were analyzed using Annexin V-FITC/PI flow cytometry.

Fraxetin purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Jul 16;10(15):e34717. [Abstract]

Cells were treated with Fraxetin (0, 80, 120, 160 μM) for 24 h, and the expression levels of apoptosis-related proteins Bax and Bcl-2 were analyzed by western blotting.
Evid Based Complement Alternat Med

Fraxetin Inhibits the Proliferation and Metastasis of Glioma Cells by Inactivating JAK2/STAT3 Signaling. [Abstract]

2021 Apr 16:2021:5540139. PMID: 33959183

Fraxetin purchased from MedChemExpress. Usage Cited in: Evid Based Complement Alternat Med. 2021 Apr 16:2021:5540139. [Abstract]

Fraxetin (100, 200 μM, 24 h) inhibits the invasion and migration of U251 cells.

Fraxetin purchased from MedChemExpress. Usage Cited in: Evid Based Complement Alternat Med. 2021 Apr 16:2021:5540139. [Abstract]

Immunofluorescence analysis of STAT3. Cells were treated with Fraxetin (0 μM, 100 μM, and 200 μM) for 24 h.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (480.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.8038 mL

24.0188 mL

48.0377 mL

5 mM

0.9608 mL

4.8038 mL

9.6075 mL

10 mM

0.4804 mL

2.4019 mL

4.8038 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (9.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (9.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (9.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 25 mg/mL (120.09 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Liu G, et al. Effect of fraxetin on proliferation and apoptosis in breast cancer cells. Oncol Lett. 2017 Dec;14(6):7374-7378. [Content Brief]

[2]. Haiting Wang, et al. Antibacterial mechanism of fraxetin against Staphylococcus aureus. Mol Med Rep. 2014 Nov;10(5):2341-5. [Content Brief]

[3]. Chen X, et al. The therapeutic effect of fraxetin on ethanol-induced hepatic fibrosis by enhancing ethanol metabolism, inhibiting oxidative stress and modulating inflammatory mediators in rats. Int Immunopharmacol. 2018 Mar;56:98-104. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.8038 mL	24.0188 mL	48.0377 mL	120.0942 mL
	5 mM	0.9608 mL	4.8038 mL	9.6075 mL	24.0188 mL
	10 mM	0.4804 mL	2.4019 mL	4.8038 mL	12.0094 mL
	15 mM	0.3203 mL	1.6013 mL	3.2025 mL	8.0063 mL
	20 mM	0.2402 mL	1.2009 mL	2.4019 mL	6.0047 mL
	25 mM	0.1922 mL	0.9608 mL	1.9215 mL	4.8038 mL
	30 mM	0.1601 mL	0.8006 mL	1.6013 mL	4.0031 mL
	40 mM	0.1201 mL	0.6005 mL	1.2009 mL	3.0024 mL
	50 mM	0.0961 mL	0.4804 mL	0.9608 mL	2.4019 mL
	60 mM	0.0801 mL	0.4003 mL	0.8006 mL	2.0016 mL
	80 mM	0.0600 mL	0.3002 mL	0.6005 mL	1.5012 mL
	100 mM	0.0480 mL	0.2402 mL	0.4804 mL	1.2009 mL

Keywords

Fraxetin

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Fraxetin

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antioxidant Compound Library

Antibacterial Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Fraxetin

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Fraxetin Related Classifications

HY-N0580 Related Classifications